A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults - Sheldon, Eric; Kitchin, Nicholas; Peng, Yahong; Eiden, Joseph; Gruber, William; Johnson, Erik; Jansen, Kathrin U.; Pride, Michael W.; Pedneault, Louise (Vaccine, 2016)
Keywords: Adjuvants, Immunologic - administration & dosage; adults; Age; Aged; Aged, 80 and over; Allergy and Immunology; Aluminum; aluminum hydroxide; Aluminum Hydroxide - administration & dosage; Antibiotics; Antibodies, Bacterial - blood; Antibodies, Neutralizing - blood; antigens; Antitoxins; bacteria; Bacterial Vaccines - administration & dosage; Bacterial Vaccines - therapeutic use; Clostridium difficile; Diarrhea; Enterocolitis, Pseudomembranous - prevention & control; Ethnicity; Female; headache; Hemophilia; Hepatitis; Hispanic Americans; Hospitals; Humans; Illnesses; Immune response; Immunization; Immunization, Secondary; Immunogenicity; Infections; injection site; Laboratories; Long term health care; Long-term care; Male; Middle Aged; morbidity; Mortality; neutralization; neutralizing antibodies; Neutralizing antibody; Nursing; nursing homes; Population; Pseudomembranous colitis; Single-Blind Method; Toxin A; Toxin B; Toxins; toxoids; Toxoids - administration & dosage; Toxoids - therapeutic use; Vaccine; Vaccines; virulence; United States--US; Toxin A; C. difficile; Toxin B; Clostridium difficile; Al(OH)3; CDI; Vaccine; Pseudomembranous colitis; PCR; Neutralizing antibody; Al(OH) 3; aluminum hydroxide; Clostridium difficile infection; polymerase chain reaction